Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda variable 3-17 (IGLV3-17) is a **pseudogene** member of the immunoglobulin lambda variable (IGLV) gene cluster in humans[1][3][4][8]. Unlike functional immunoglobulin variable genes, **IGLV3-17 does not encode a functional protein** and is not involved in forming the antigen-binding domains of immunoglobulins (antibodies)[1][3]. The IGLV gene family consists of both functional genes and pseudogenes; IGLV3-17 is classified as a pseudogene, meaning it has lost its protein-coding potential through mutations[5]. IGLV3-17 is **not considered a therapeutic target** (such as a receptor, enzyme, transporter, etc.), nor is it known to have a disease association, biomarker role, or interaction with drugs[1][3][4][8]. It is referenced in gene nomenclature resources as part of the broader immunoglobulin lambda variable gene cluster, but specific roles or mechanisms of action do not apply to this locus due to its pseudogene status[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda variable 3-17 (pseudogene) (IGLV3-17).